![](/img/cover-not-exists.png)
Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: A randomized, double-blind, controlled, parallel-group, Phase 2b trial: Discussions from a Twitter journal club @respandsleepjc (#rsjc)
Kawala, Christopher, Anand, Anju, Stanbrook, MatthewJournal:
Canadian Journal of Respiratory, Critical Care, and Sleep Medicine
DOI:
10.1080/24745332.2020.1777598
Date:
August, 2020
File:
PDF, 687 KB
2020